KR19980048265A - New external preparation composition - Google Patents

Abstract

The present invention provides a topical formulation containing a base component and a hydrophobic active ingredient, wherein both the carbopol and polysaccharides are contained as the base component, and the hydrophobic active ingredient is a hydrophobic drug.

The external preparations according to the present invention have the advantage of remarkably improving the skin permeability of the hydrophobic active ingredient and excellent product stability.

Description

New external preparation composition

The present invention relates to an external preparation composition, and more particularly, to an external preparation composition that significantly improved the skin absorption of the hydrophobic drug contained as an active ingredient.

As a hydrophobic drug, antibiotics, such as cefoxidine, erythromycin, or gentamicin; Bronchodilators such as deophylline; Antihistamines such as diphenhydramine, chlorphenylamine, promethazine, cycline, carbinosamine, ciprohaptadine or dimethidine; And ronazolac calcium salts, ketoprofen, ibuprofen, flurbiprofen, naproxen, fenofurofen, venoxapropene, indopropene, pipeurofen, capurofen, oxaprozin, pranofuropene, water Nonsteroidal anti-inflammatory drugs such as propene, aminofurophene, butybufen or penbufen. Among these, nonsteroidal anti-inflammatory drugs have strong anti-inflammatory and analgesic effects, and thus, treatment of rheumatoid arthritis and related diseases such as chronic arthritis, degenerative arthritis, low back pain, pneumoconvulsion syndrome, and severe neuralgia and related postoperative trauma. It is widely used for analgesic and anti-inflammatory.

Conventionally, these preparations have been generally solidified into tablets, capsules, and the like, orally administered, and have been reported to exhibit excellent clinical efficacy. However, after oral administration of these drugs usually taken for a long time, there were problems such as systemic side effects, particularly irritating the gastrointestinal tract.

In order to reduce these side effects, many studies have been conducted to formulate these drugs for administration other than oral administration, especially for transdermal administration. For example, Japanese Patent Application Laid-Open Nos. 58-39616, 58-83622, 58-103311, 61-238723, US Patent 4,393,076, 4,534,980, and Korean Patent Publication No. 96-428 and the like. It has been shown that steroidal anti-inflammatory drugs are designed as external preparations, especially mainly ointments, creams and gels. According to these, carbopol, hydroxypropylmethylcellulose, and pluronic are used as a base for designing propionic acid nonsteroidal anti-inflammatory drugs as external preparations, and systemic side effects are maintained while maintaining the efficacy of drugs similar to oral administration. And gastrointestinal stimulation has been significantly reduced.

However, in the prior art, although systemic side effects and gastrointestinal stimulation are reduced, skin permeation of the drug is not satisfactory yet, and hydroxypropylmethylcellulose and pluronic are poor in use, such as stickiness in use.

Accordingly, an object of the present invention is to provide an external preparation for improving the percutaneous absorption of hydrophobic drugs while reducing side effects and improving the usability.

According to an aspect of the present invention, there is provided an external preparation containing a base component and a hydrophobic active ingredient, wherein the external preparation comprises carbopol and polysaccharides together as the base component.

According to another aspect of the present invention, an external preparation containing a base ingredient and a hydrophobic active ingredient, wherein the external ingredient contains carbopol and polysaccharides as the base ingredient, and the hydrophobic active ingredient is a hydrophobic drug. Is provided.

The above and other objects and features of the present invention will become apparent to those skilled in the art by the following detailed description.

Hereinafter, the present invention will be described in more detail.

The oily component added to the external preparation of the present invention includes a hydrophobic substance.

Among the hydrophobic substances, in particular hydrophobic drugs, in particular rhoazolak calcium salt, sepoxidine erythromycin, gentamicin, deophylline, diphenhydramine, chlorophenylamine, promethazine, cycline, carbinosamine, ciprohap Tadine, dimethidine and propionic acid nonsteroidal anti-inflammatory drugs include ketoprofen, flurbiprofen, ibuprofen, naproxen, phenofrufen, benoxaprofen, indopropene, pipeurofen, capurofen, 1 type, or 2 or more types chosen from an oxa propazine, a pranopurofen, a suprofen, an aminofurofen, butoxybufen, and a penbufen. In addition, other hydrophobic drugs similar in physical and chemical properties to the aforementioned drugs may be used together.

These hydrophobic active ingredients are combined in amounts of 0.5-10% by weight based on the total weight of the formulation composition.

The external preparations according to the invention also contain carbopol and polysaccharide together as a base. When Carbopol and Polysaccharide are used together, the combination of Carbopol and Polysaccharide provides the advantage of freely changing the physical properties of the external preparation, and surprisingly promotes skin penetration of hydrophobic active ingredients compared to the use alone. It shows an effect. Carbopol is used in amounts of 0.5-2.5% by weight and polysaccharides in amounts of 0.01-10% by weight.

Carbomers (or carbopol resins) used in the present invention are acrylic polymers having a floppy and dry powdery (100% effect) properties. Carbopol resin is a type of water-soluble resin that has a function of increasing, dispersing, and emulsion-based resistance to bacteria attack, and is a mechanism that can be used for external preparations while preventing the growth of fungi.

The polysaccharide used in the present invention is a high molecular compound produced by condensation of 7 or more molecules of monosaccharides, and generally swells in water to form a colloidal solution. Specifically, dextran, pullulan, kudran, scregururan, levan, alginite, xanthan, phosphomannan, zanpro, hyaluronic acid and salts and derivatives thereof can be exemplified.

In addition, the external preparations according to the invention are also lower alcohols, methyl pyrrolidone, terpineol, polyethylene sorbitan fatty acid esters, polyoxyethylene oleyl ether, polyoxyethylene lauryl ether, propylene glycol fatty acid esters, hexylene glycol And a mixture consisting of at least one reagent selected from transcutol and preservatives, etc., if necessary, by adding water or a neutralizing agent (for example, triethanololamine or neutrol triethanolamine), and homogeneously mixing and dissolving the mixture to prepare an external preparation. will be. If necessary, skin stimulants or preservatives such as menthol, camphor, euchariftus oil and mexican can be added.

As the lower alcohol used in the present invention, ethanol or isopropyl alcohol and the like can be exemplified.

As the polyethylene sorbitan fatty acid esters, Tweens, for example, Tween 20, Tween 40, Tween 60, Tween 80 and the like can be used.

As the preservative, benzoic acid, soda benzoic acid, paraoxybenzoic acid methyl ester or paraoxybenzoic acid ethyl ester, paraoxybenzoic acid propyl ester, paraoxybenzoic acid butyl ester or a mixture of two or more thereof can be used.

In addition, one or two or more selected from methyl pyrrolidone, terpineol, polyethylene sorbitan fatty acid ester, polyoxyethylene oleyl ether, polyoxyethylene lauryl ether, propylene glycol fatty acid ester, hexylene glycol and transcutol When used, the amount is selected within the range of 0.5-15% by weight relative to the total weight of the composition.

In the external preparations of the present invention, carbopol and polysaccharide form a thin film when applied to the skin, and slowly release hydrophobic drugs therefrom, and the effect of the drug is sustained and has an excellent effect. In addition, polysaccharides have a skin moisturizing and protective action, thus protecting the skin from the outside and promoting the skin penetration of drugs. Transcutol, methyl pyrrolidone, terpineol, polyethylene sorbitan fatty acid ester, polyoxyethylene oleyl ether, polyoxyethylene lauryl ether, propylene glycol fatty acid ester, hexylene glycol disperse the drug evenly as a solvent or dissolution aid Stabilizes and promotes skin penetration of drugs.

In addition to the external preparation of the present invention, it may further contain appropriate conventional ingredients according to the formulation. The topical preparations of the invention may be prepared in conventional formulations, in particular in the form of ointments, gels, lotions, creams, or patches. The preparation method according to the formulation is well known in the art, and the present invention is not limited by the particular formulation or its preparation method.

For example, when formulated as a gel preparation, it may be prepared by the following method.

The drug is prepared by dissolving the drug in low alcohol and mixing it in a homogeneous state with a solution of carbopol or polysaccharide prepared in advance, and adding other additives thereto. At this time, a lower alcohol may be added a solution of skin preservatives such as menthol and preservatives.

The external preparations of the hydrophobic drugs prepared in this way not only had a good appearance but also had no side effects on the skin. As shown in the reference example below, the skin absorption was superior to the existing preparations, and the drug was gradually absorbed and the effect was also weak. It lasted for one day.

Hereinafter, the present invention will be described with reference to specific examples, but the present invention is not limited thereto. However,% in this specification and an Example means weight% unless there is particular notice. The prepared formulations were stored at room temperature.

Example 1: Gel

Ketoprofen 3%

Carbopol 940 1.5%

Hyaluronic Acid 0.1%

Ethanol 35%

Emalex 506 8%

Neutrol Tee 0.5%

51.9% of water

Dissolve 3 g of ketoprofen in 35 g of ethanol, add 1.5 g of Carbopol 940 and 0.1 g of hyaluronic acid to a solution dissolved in water, mix well, mix Emalex 506, and then mix Neutrolti Make a festival

Comparative Example 1-1

Ketoprofen 3%

Carbopol 940 1.5%

Ethanol 35%

Neutrolti 0.5%

60% of water

For the purpose of comparison, a ketoprofen external preparation was prepared according to the method according to Example 1 for the external preparation consisting only of a drug and a base.

Comparative Example 1-2

Ketoprofen 3%

Carbopol 940 1.5%

Ethanol 35%

Emalex 506 8%

Neutrolti 0.5%

52% of water

For the purpose of comparison, an external preparation consisting solely of a drug, a base, and an emulsifier (absorption accelerator) was prepared according to the method according to Example 1, and a ketoprofen external preparation was prepared.

Comparative Example 1-3

Ketoprofen 3%

Pluronic F-127 15%

Polyethylene glycol 300 3%

Ethanol 18.5%

Menthol 0.3%

Paraoxybenzoic acid methyl ester 0.17%

Paraoxybenzoic acid propyl ester 0.02%

pH 4.5 buffer 60.01%

3 g of ketoprofen and 15 g of Pluronic F-127 were melted by heating at 105 ° C. for 10 minutes and then cooled to 60 ° C. Separately, pH 4.5 buffer in which 0.17 g of paraoxybenzoic acid methyl ester and 0.02 g of paraoxybenzoic acid propyl ester were mixed, 18.5 g of ethanol in which 0.3 g of menthol and 3 g of polyethylene glycol 300 were mixed, and then mixed with the molten mixture at 60 ° C. The ketoprofen external preparation was obtained.

Example 2

Ketoprofen 3%

Carbopol 940 1.5%

Hyaluronic Acid 0.1%

Ethanol 35%

Emalex 506 8%

Twin 80 5%

Neutrol Tee 0.5%

46.9% of water

Ketoprofen external preparation was prepared using the same method as in Example 1.

Example 3

Ibuprofen 3%

Carbopol 940 1.5%

Hyaluronic Acid 0.1%

Ethanol 35%

Emalex 506 8%

Neutrol Tee 0.5%

51.9% of water

The ibuprofen external preparation was prepared using the same method as in Example 1.

Comparative Example 3-1

Ibuprofen 3%

Carbopol 940 1.5%

Ethanol 35%

Neutrolti 0.5%

60% of water

For the purpose of comparison, an external preparation consisting solely of drugs and bases was prepared according to the method according to Example 3.

Comparative Example 3-2

Ibuprofen 3%

Carbopol 940 1.5%

Ethanol 35%

Emalex 506 8%

Neutrolti 0.5%

52% of water

For the purpose of comparison, an external preparation consisting of only a drug, a base, and an emulsifier (absorption accelerator) was prepared according to the method according to Example 3.

Comparative Example 3-3

Ibuprofen 3%

Pluronic F-127 15%

Polyethylene glycol 300 3%

Ethanol 18.5%

Menthol 0.3%

Paraoxybenzoic acid methyl ester 0.17%

Paraoxybenzoic acid propyl ester 0.02%

pH 4.5 buffer 60.01%

An ibuprofen external preparation was prepared in the same manner as in Comparative Example 1-3.

Example 4

Flubifurofen 3%

Carbopol 940 1.5%

Hyaluronic Acid 0.1%

Ethanol 35%

Emalex 506 8%

Neutrol Tee 0.5%

51.9% of water

Fluvifurofen external preparation was prepared in the same manner as in Example 1.

Comparative Example 4-1

Flubifurofen 3%

Carbopol 940 1.5%

Ethanol 35%

Neutrolti 0.5%

60% of water

For the purpose of comparison, an external preparation consisting solely of drugs and bases was prepared according to the method according to Example 1.

Comparative Example 4-2

Flubifurofen 3%

Carbopol 940 1.5%

Ethanol 35%

Emalex 506 8%

Neutrolti 0.5%

52% of water

For the purpose of comparison, an external preparation consisting of only a drug, a base, and an emulsifier (absorption accelerator) was prepared according to the method according to Example 1.

Comparative Example 4-3

3% of fluvifurofen

Pluronic F-127 15%

Polyethylene glycol 300 3%

Ethanol 18.5%

Menthol 0.3%

Paraoxybenzoic acid methyl ester 0.17%

Paraoxybenzoic acid propyl ester 0.02%

pH 4.5 buffer 60.01%

Flubifurophene formulations were prepared in the same manner as in Comparative Examples 1-3.

Example 5

Theophyrin 3%

Carbopol 940 1.5%

Hyaluronic Acid 0.1%

Ethanol 35%

Emalex 506 8%

Neutrol Tee 0.5%

51.9% of water

Theophyrin external preparations were prepared in the same manner as in Example 1.

Comparative Example 5-1

Theophylline 3%

Carbopol 940 1.5%

Ethanol 35%

Neutrolti 0.5%

60% of water

For the purpose of comparison, an external preparation consisting solely of drugs and bases was prepared according to the method according to Example 1.

Comparative Example 5-2

Theophylline 3%

Carbopol 940 1.5%

Ethanol 35%

Emalex 506 8%

Neutrolti 0.5%

52% of water

For the purpose of comparison, an external preparation consisting of only a drug, a base, and an emulsifier (absorption accelerator) was prepared according to the method according to Example 1.

Comparative Example 5-3

Theophylline 3%

Pluronic F-127 15%

Polyethylene glycol 300 3%

Ethanol 18.5%

Menthol 0.3%

Paraoxybenzoic acid methyl ester 0.17%

Paraoxybenzoic acid propyl ester 0.02%

pH 4.5 buffer 60.01%

Theophylline external preparation was manufactured by the same method as the comparative example 1-3.

Example 6

Erythromycin 3%

Carbopol 940 1.5%

Dextran 1%

Ethanol 35%

Emalex 506 8%

Neutrol Tee 0.5%

51% of water

The erythromycin external preparation was prepared in the same manner as in Example 1.

Comparative Example 6-1

Erythromycin 3%

Carbopol 940 1.5%

Ethanol 35%

Neutrolti 0.5%

60% of water

For the purpose of comparison, an external preparation consisting solely of drugs and bases was prepared according to the method according to Example 1.

Comparative Example 6-2

Erythromycin 3%

Carbopol 940 1.5%

Ethanol 35%

Emalex 506 8%

Neutrolti 0.5%

52% of water

For the purpose of comparison, an external preparation consisting of only a drug, a base, and an emulsifier (absorption accelerator) was prepared according to the method according to Example 1.

Comparative Example 6-3

Erythromycin 3%

Pluronic F-127 15%

Polyethylene glycol 300 3%

Ethanol 18.5%

Menthol 0.3%

Paraoxybenzoic acid methyl ester 0.17%

Paraoxybenzoic acid propyl ester 0.02%

pH 4.5 buffer 60.01%

An erythromycin external preparation was prepared in the same manner as in Comparative Example 1-3.

Example 7

Diphenhydramine 3%

Carbopol 940 1.5%

Hyaluronic Acid 0.1%

Ethanol 35%

Emalex 506 8%

Neutrol Tee 0.5%

51.9% of water

Diphenhydramine external preparation was prepared in the same manner as in Example 1.

Comparative Example 7-1

Diphenhydramine 3%

Carbopol 940 1.5%

Ethanol 35%

Neutrolti 0.5%

60% of water

For the purpose of comparison, an external preparation consisting solely of drugs and bases was prepared according to the method according to Example 1.

Comparative Example 7-2

Diphenhydramine 3%

Carbopol 940 1.5%

Ethanol 35%

Emalex 506 8%

Neutrolti 0.5%

52% of water

For the purpose of comparison, an external preparation consisting of only a drug, a base, and an emulsifier (absorption accelerator) was prepared according to the method according to Example 1.

Comparative Example 7-3

Diphenhydramine 3%

Pluronic F-127 15%

Polyethylene glycol 300 3%

Ethanol 18.5%

Menthol 0.3%

Paraoxybenzoic acid methyl ester 0.17%

Paraoxybenzoic acid propyl ester 0.02%

pH 4.5 buffer 60.01%

A diphenhydramine external preparation was prepared in the same manner as in Comparative Example 1-3.

Example 8 (Ointment)

Naproxen 5%

Cabopol 9400.5%

Alginate 5%

Ethanol 15%

Hexylene glycol 8%

Propylene Glycol 1000 20%

46.5% of water

Naproxen 5%, Hexylene Glycol 8%, Propylene Glycol 1000 I made an ointment.

Comparative Example 8-1

Naproxen 5%

Cabopol 9400.5%

Ethanol 15%

Propylene Glycol 1000 20%

59.5% of water

For the purpose of comparison, an external preparation consisting solely of drugs and bases was prepared according to the method according to Example 1.

Comparative Example 8-2

Naproxen 5%

Cabopol 9400.5%

Ethanol 15%

Hexylene glycol 8%

Propylene Glycol 1000 20%

51.5% of water

For the purpose of comparison, an external preparation consisting solely of a drug and a base and an emulsifier (absorption accelerator) was prepared according to the method according to Example 1.

Comparative Example 8-3

Naproxen 5%

Pluronic F-127 15%

Polyethylene glycol 300 3%

Ethanol 18.5%

Menthol 0.3%

Paraoxybenzoic acid methyl ester 0.17%

Paraoxybenzoic acid propyl ester 0.02%

pH 4.5 buffer58.01%

A naproxen external preparation was prepared in the same manner as in Comparative Example 1-3.

Example 9 (creaming agent)

Ronazolac Calcium 5%

Cabopol 0.5%

Xanthan 2%

Isopropanol 10%

Twin 20 5%

Transcutol 15%

Propylene Glycol 1000 20%

42.5% of water

Mix well with 5% Ronazolac calcium, 5% Tween 20, and 20% Propylene Glycol 300, and then mix it evenly with a solution prepared with 0.5% Carbopol 940, 2% Xanthan, 10% Isopropanol and 42.5% water. Ronazolac calcium external cream was made.

Comparative Example 9-1

Ronazolac calcium 5%

Cabopol 0.5%

Isopropanol 10%

Propylene Glycol 300 20%

Water 6.65%

For the purpose of comparison, an external preparation consisting solely of drugs and bases was prepared according to the method according to Example 1.

Comparative Example 9-2

Ronazolac Calcium 5%

Cabopol 0.5%

Isopropanol 10%

Twin 20 5%

Transcutol 15%

Propylene Glycol 300 20%

44.5% of water

For the purpose of comparison, an external preparation consisting solely of a drug and a base and an emulsifier (absorption accelerator) was prepared according to the method according to Example 1.

Comparative Example 9-3

Ronazolac calcium 5%

Pluronic F-127 15%

Polyethylene glycol 300 3%

Ethanol 18.5%

Menthol 0.3%

Paraoxybenzoic acid methyl ester 0.17%

Paraoxybenzoic acid propyl ester 0.02%

pH 4.5 buffer58.01%

A naproxen external preparation was prepared in the same manner as in Comparative Example 1-3.

Example 10 (creaming agent)

Gentamicin 5%

Cabopol 940 0.5%

Hyaluronic Acid0.8%

Alginate 1%

Ethanol 20%

Terpineol 13%

Paraoxybenzoic Acid Methyl Ester 0.17%

Paraoxybenzoic acid propyl ester 0.02%

Water59.51%

Gentamycin 5% and terpineol 13% were mixed well, and then mixed with a solution prepared in advance with 0.5% carbopol 940, 0.8% hyaluronic acid, 1% alginate, 59.51% water, and then paraoxy Gentamicin external cream was prepared by dissolving benzoic acid methyl ester and paraoxybenzoic acid propyl ester.

Comparative Example 10-1

Gentamicin 5%

Cabopol 940 0.5%

Ethanol 20%

Paraoxybenzoic Acid Methyl Ester 0.17%

Paraoxybenzoic acid propyl ester 0.02%

Water74.31%

For the purpose of comparison, an external preparation consisting solely of drugs and bases was prepared according to the method according to Example 1.

Comparative Example 10-2

Gentamicin 5%

Cabopol 940 0.5%

Ethanol 20%

Terpineol 13%

Paraoxybenzoic Acid Methyl Ester 0.17%

Paraoxybenzoic acid propyl ester 0.02%

61.31% of water

For the purpose of comparison, an external preparation consisting of a drug, a base, and an emulsifier (absorption accelerator) was prepared according to the method according to Example 1.

Comparative Example 10-3

Gentamicin 5%

Pluronic F-127 15%

Polyethylene glycol 300 3%

Ethanol 18.5%

Menthol 0.3%

Paraoxybenzoic Acid Methyl Ester 0.17%

Paraoxybenzoic acid propyl ester 0.02%

pH 4.5 buffer58.01%

It prepared in the same manner as in Comparative Example 1-3.

Experimental Example 1. Stability test of the formulation

In the stability test of the formulation, the state of the formulation was observed after 6 months at 4 ° C, 25 ° C and 40 ° C, and the results are shown in Table 1. Observation items were appearance and content (%). The content of each drug was measured using the method described in the Korean Pharmacopoeia or public health notice.

TABLE 1

Stability test results for each prescription stored at 4 ℃, 25 ℃ and 40 ℃ for 6 months

*:% Relative to original content.

As shown in Table 1, it was confirmed that the external preparations of the hydrophobic drug according to the present invention have considerable stability.

Experimental Example 2. Skin Permeability of Drug

Skin of male Hartley-based guinea pigs weighing 330g-370g was used for the experiment. The guinea pigs were de-golsted and the hairs of the belly were carefully removed using a hair removal machine (Diatoelectric Co., Japan). After removal of the ventral skin of approximately 6 Cm × 8 Cm area, the subcutaneous fat and tissues attached under the skin were carefully removed so as not to damage the skin. Extracted skin was stored at -20 ℃ before use.

The drug permeation rate was measured by using a Franze cell and the rate of skin penetration of each drug through the skin extracted from external preparations. The skin area in contact with the receptor phase was 0.50 cm 2 and the volume of the receptor phase was 5 ml. The receptor phase was filled with pH 7.4 phosphate buffer (0.05M) and the temperature was maintained at 37 ± 0.5 ° C. Receptor phase was constantly stirred at 1800rpm using a magnetic bar and a magnetic stirrer.

Before starting the experiment, the frozen skin was dissolved at room temperature, soaked with pH 7.4 phosphate buffer solution (0.05M) at 37 ° C, and the extracted skin was fixed between the donor and receptor phases. About 1 ml of each prepared external preparation was administered to the skin surface and samples were quantified 4 hours after removing the air bubbles on the skin surface, and each prescription was tested four times and then the average value was obtained. The drug permeability of the formulation of each Example was set to 1, and the drug skin permeability of the formulation of the corresponding comparative example was shown as a relative value.

[Table 2]

Drug permeability for each example.

As shown in Table 2, when using the method of the present invention it was confirmed that the skin permeation of the drug increases from as little as 2.22 times to as much as 12.5 times.

In the above examples, six hydrophobic active ingredients, especially ketoprofen, ibuprofen, flubifuropene, theophyrin, erythromycin, and diphenhydramine, were used as hydrophobic drugs, but in addition to the other hydrophobic drugs described herein, It should be borne in mind that the present invention applies.

As described above, the composition of the external preparation according to the present invention shows a very excellent effect in greatly improving the stability of the hydrophobic drug and the skin drug permeability.

Claims (5)

An external preparation containing a base component and a hydrophobic active ingredient, wherein the external preparation composition contains carbomer and polysaccharides together as the base component. The external preparation composition according to claim 1, wherein the hydrophobic active ingredient is a hydrophobic drug. The method of claim 2, wherein the hydrophobic drug is sepoxidine, erythromycin, gentamicin, deophylline, diphenhydramine, chlorophenylamine, promethazine, cyclrizine, carbinosamine, ciprohaptadine, dimethy Dean, Ronazolaccalsalt, Ketoprofen, Flubiprofen, Ibuprofen, Naproxen, Phenofurfen, Benoxapropene, Indopropene, Pipeurofen, Capurofen, Oxaprozin, Pranopurofen, An external preparation composition comprising one or two or more drugs selected from the group consisting of supropene, aminofurofen, butoxybufen and penbufen, in an amount of 0.5 to 10% by weight based on the total weight of the composition. The polysaccharide according to any one of claims 1 to 3, wherein the polysaccharide is selected from dextran, pullulan, kudran, scregururan, levan, alginate, xanthan, phosphomannan, zanpro, hyaluronic acid and An external preparation composition comprising one or two or more selected from the group consisting of salts and derivatives, and formulated in an amount of 0.01 to 10% by weight, based on the total weight of the composition. 4. A composition according to any one of claims 1 to 3, comprising 0-40% by weight of lower alcohols relative to the total weight of the composition; And methyl pyrrolidone, terpineol, polyethylene sorbitan fatty acid ester, polyoxyethylene oleyl ether, polyoxyethylene lauryl ether, propylene glycol fatty acid ester, hexylene glycol and diethylene glycol monoethyl ether An external preparation composition, characterized in that 0.5 to 15% by weight of each component is blended as one kind or a mixture of two or more kinds.